AXIM AXIM BIOTECHNOLOGIES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31
Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%
Returns
ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 | 2022Q32022-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17,479 | $52,979 | $12,859 | $9,581 | $9,929 | $7,397 | $7,561 | $1,314 |
| Cost of revenue | $1,744 | — | — | — | $0 | — | — | — |
| Gross profit | $15,735 | — | — | — | $9,929 | — | — | $1,314 |
| R&D expense | $4,063 | $15,495 | $36,373 | $34,713 | $34,074 | $20,336 | $44,611 | $29,722 |
| SG&A expense | $472,984 | $331,040 | $623,671 | $456,648 | $566,829 | $590,940 | $998,475 | $1.18M |
| Operating income | -$569,441 | -$401,563 | -$753,940 | -$588,535 | -$697,729 | -$710,634 | -$1.14M | -$1.32M |
| Interest expense | $178,244 | -$163,597 | -$734,002 | $64,658 | $751,505 | -$57,839 | -$1.37M | $57,481 |
| Pretax income | -$2.27M | -$292,299 | -$1.90M | $328,470 | -$3.72M | -$2.76M | -$899,050 | -$2.03M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.27M | -$292,299 | -$1.90M | $328,470 | -$3.72M | -$2.76M | -$899,050 | -$2.03M |
| EBITDA | -$461,312 | -$293,556 | -$647,185 | -$481,780 | -$590,974 | -$603,879 | -$1.04M | -$1.21M |
| EPS (basic) | -0.01 | -0.00 | — | 0.00 | -0.02 | -0.01 | — | -0.01 |
| EPS (diluted) | -0.01 | -0.00 | — | 0.00 | -0.02 | -0.01 | — | -0.01 |
| Weighted avg. shares (diluted) | — | — | — | 478.51M | 226.26M | — | — | — |
| Banking | ||||||||
| Noninterest expense | — | — | -$690,000 | $0 | — | — | -$1.14M | $0 |
| Balance sheet | ||||||||
| Cash & equivalents | $6,044 | $96,711 | $156,457 | $23,220 | $97,498 | $53,542 | $47,282 | $163,746 |
| Inventory | — | — | — | — | — | — | — | $20,089 |
| Current assets | $20,243 | $96,711 | $156,457 | $23,220 | $97,498 | $56,556 | $103,979 | $249,225 |
| PP&E, net | $117,993 | $127,510 | $134,067 | $69,410 | $77,554 | $85,697 | $93,840 | $102,069 |
| Intangibles | — | — | — | $3.69M | $3.79M | — | $3.99M | — |
| Total assets | $3.73M | $3.93M | $4.12M | $4.04M | $4.25M | $4.04M | $4.21M | $4.48M |
| Current liabilities | $6.57M | $4.80M | $5.98M | $4.28M | $8.37M | $4.86M | $3.39M | $3.16M |
| Short-term debt | $92,645 | $91,306 | $94,829 | $91,672 | $88,475 | $4,984 | $19,789 | — |
| Long-term debt | $93,847 | $118,031 | $137,044 | — | — | — | — | — |
| Total debt | $186,492 | $209,337 | $231,873 | — | — | — | — | — |
| Total liabilities | $13.26M | $11.38M | $11.78M | $10.00M | $14.00M | $10.20M | $9.04M | $8.86M |
| Shareholders' equity | -$9.53M | -$7.45M | -$7.66M | -$5.96M | -$9.75M | -$6.16M | -$4.83M | -$4.38M |
| Net debt | $180,448 | $112,626 | $75,416 | — | — | — | — | — |
| Shares outstanding | 294.46M | 278.43M | 245.93M | 237.65M | 227.65M | 223.65M | 192.44M | 138.10M |
| Cash flow statement | ||||||||
| Operating cash flow | $553,013 | -$252,506 | $19,556 | -$264,503 | -$643,594 | -$141,959 | -$315,505 | -$321,225 |
| Capital expenditure | — | $2,839 | $0 | — | — | — | $0 | $2,710 |
| Free cash flow | — | -$255,345 | $19,556 | — | — | — | -$315,505 | -$323,935 |
| Investing cash flow | $0 | -$2,839 | $0 | $0 | $0 | $0 | $0 | -$2,710 |
| Financing cash flow | -$643,680 | $195,599 | $113,681 | $190,225 | $687,550 | $148,219 | $199,041 | $422,518 |
| Depreciation & amortization | $108,129 | $108,007 | $106,755 | $106,755 | $106,755 | $106,755 | $106,840 | $106,744 |
| Stock-based compensation | $9,613 | $9,613 | $34,086 | $38,415 | $21,404 | $103,822 | $219,181 | $517,180 |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.